Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial

被引：0

作者：

Fiona Gaughran

Dominic Stringer

Michael Berk

Shubulade Smith

David Taylor

Eromona Whiskey

Sabine Landau

Robin Murray

Philip McGuire

Poonam Gardner-Sood

Gabriella Wojewodka

Simone Ciufolini

Harriet Jordan

Jessie Clarke

Lauren Allen

Amir Krivoy

Brendon Stubbs

Philippa Lowe

Maurice Arbuthnott

Shanaya Rathod

Andrew Boardman

Mudasir Firdosi

John J. McGrath

机构：

[1] King’s College London,Department of Psychosis Studies

[2] Institute of Psychiatry,Department of Biostatistics and Health Informatics

[3] Psychology and Neuroscience,Clinical Trials Facility, Research Department, Tom Rudd Unit

[4] South London and Maudsley NHS Foundation Trust,National Centre for Register

[5] King’s College London,Based Research

[6] Institute of Psychiatry,undefined

[7] Psychology and Neuroscience,undefined

[8] Deakin University and Barwon Health,undefined

[9] Carer Expert and Chair of Trustees,undefined

[10] Rethink Mental Illness,undefined

[11] Moorgreen Hospital,undefined

[12] Cheshire & Wirral Partnership NHS Trust,undefined

[13] Churton House,undefined

[14] South West London and St George’s Mental Health NHS Trust,undefined

[15] Queen Mary’s Hospital,undefined

[16] Queensland Centre for Mental Health Research,undefined

[17] The Park Centre for Mental Health,undefined

[18] Queensland Brain Institute,undefined

[19] University of Queensland,undefined

[20] Aarhus University,undefined

来源：

Trials | / 21卷

关键词：

Psychosis; First episode; Vitamin D; 25OHD; Randomised controlled trial; Positive and Negative Syndrome Scale; Mental health;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Vitamin D supplementation compared to placebo in people with First Episode psychosis-Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
Gaughran, Fiona
Stringer, Dominic
Berk, Michael
Smith, Shubulade
Taylor, David
Whiskey, Eromona
Landau, Sabine
Murray, Robin
McGuire, Philip
Gardner-Sood, Poonam
Wojewodka, Gabriella
Ciufolini, Simone
Jordan, Harriet
Clarke, Jessie
Allen, Lauren
Krivoy, Amir
Stubbs, Brendon
Lowe, Philippa
Arbuthnott, Maurice
Rathod, Shanaya
Boardman, Andrew
Firdosi, Mudasir
McGrath, John J.
TRIALS, 2020, 21 (01)
[2] Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
Kapoor, Raju
Furby, Julian
Hayton, Thomas
Smith, Kenneth J.
Altmann, Daniel R.
Brenner, Robert
Chataway, Jeremy
Hughes, Richard A. C.
Miller, David H.
LANCET NEUROLOGY, 2010, 9 (07): : 681 - 688
[3] Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial
Saraux, Alain
Alegria, Guillermo Carvajal
Dernis, Emmanuelle
Roux, Christian
Richez, Christophe
Tison, Alice
Quere, Baptiste
Jousse-Joulin, Sandrine
Guellec, Dewi
Marhadour, Thierry
Kervarrec, Patrice
Cornec, Divi
Le Henaff, Catherine
Lesven, Sandra
Nowak, Emmanuel
Souki, Aghiles
Devauchelle-Pensec, Valerie
LANCET RHEUMATOLOGY, 2025, 7 (04):
[4] Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial
Goudie, Andrew R.
Lipworth, Brian J.
Hopkinson, Pippa J.
Wei, Li
Struthers, Allan D.
LANCET RESPIRATORY MEDICINE, 2014, 2 (04): : 293 - 300
[5] Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophrenia
Siskind, Dan
Bull, Claudia
Suetani, Shuichi
Warren, Nicola
Suraev, Anastasia
Mcgregor, Iain
Kisely, Steve
De Monte, Veronica
Trott, Mike
Shine, Manju
Moudgil, Vikas
Robinson, Gail
Parker, Stephen
Krishnaiah, Ravikumar
Stedman, Terry
Drummond, Allan
Medland, Sarah
Iyer, Ravi
Baker, Andrea
BJPSYCH OPEN, 2024, 10 (05):
[6] Vitamin D supplementation for primary dysmenorrhea: a double-blind, randomized, placebo-controlled trial
Rahnemaei, Fatemeh Alsadat
Gholamrezaei, Ali
Afrakhteh, Maryam
Zayeri, Farid
Vafa, Mohammad Reza
Rashidi, Arian
Ozgoli, Giti
OBSTETRICS & GYNECOLOGY SCIENCE, 2021, 64 (04) : 353 - 363
[7] Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease
Suzuki, Masahiko
Yoshioka, Masayuki
Hashimoto, Masaya
Murakami, Maiko
Noya, Miki
Takahashi, Daisuke
Urashima, Mitsuyoshi
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2013, 97 (05): : 1004 - 1013
[8] Vitamin D supplementation in subjects with hypovitaminosis D: a randomized double-blind, placebo-controlled trial
Nugroho, Heri
Tjokorda, G. D. P.
Suhartono, Tony
Darmono
BALI MEDICAL JOURNAL, 2021, 10 (01) : 405 - 411
[9] Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
Pasquale Caponnetto
Davide Campagna
Jasjit S. Ahluwalia
Christopher Russell
Marilena Maglia
Paolo Marco Riela
Carmelo Fabio Longo
Barbara Busa
Riccardo Polosa
BMC Medicine, 21
[10] Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
Caponnetto, Pasquale
Campagna, Davide
Ahluwalia, Jasjit S.
Russell, Christopher
Maglia, Marilena
Riela, Paolo Marco
Longo, Carmelo Fabio
Busa, Barbara
Polosa, Riccardo
BMC MEDICINE, 2023, 21 (01)

← 1 2 3 4 5 →